{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:25:51Z","timestamp":1749191151348},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T00:00:00Z","timestamp":1424822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00345-015-1519-2","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T07:33:33Z","timestamp":1424763213000},"page":"697-706","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH"],"prefix":"10.1007","volume":"33","author":[{"given":"Nadir I.","family":"Osman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Eisenhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Oelke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,25]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/archinte.166.21.2381","volume":"166","author":"V Kupelian","year":"2006","unstructured":"Kupelian V, Wei JT, O\u2019Leary MP, Kusek JW, Litman HJ, Link CL, McKinlay JB, BACH survey investigators (2006) Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Int Med 166:2381\u20132387","journal-title":"Arch Int Med"},{"key":"1519_CR2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474\u2013479","journal-title":"J Urol"},{"issue":"Suppl 3","key":"1519_CR3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1464-410X.2009.08369.x","volume":"103","author":"CC Sexton","year":"2009","unstructured":"Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, Aiyer LP, Tubaro A, Chapple CR, Wein AJ, EpiLUTS Team (2009) The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA UK and Sweden: EpiLUTS. BJU Int 103(Suppl 3):12\u201323","journal-title":"BJU Int"},{"key":"1519_CR4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/nau.21097","volume":"30","author":"GA Koeveringe van","year":"2011","unstructured":"van Koeveringe GA, Vahabi B, Andersson KE, Kirschner-Hermanns R, Oelke M (2011) Detrusor underactivity: a plea for new approaches to a common bladder dysfunction. Neurourol Urodyn 30:723\u2013728","journal-title":"Neurourol Urodyn"},{"key":"1519_CR5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2008.02.017","volume":"54","author":"M Oelke","year":"2008","unstructured":"Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, H\u00f6fner K (2008) Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 54:419\u2013426","journal-title":"Eur Urol"},{"key":"1519_CR6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","volume":"49","author":"CR Chapple","year":"2006","unstructured":"Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49:651\u2013658","journal-title":"Eur Urol"},{"key":"1519_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N\u2019Dow J, Nordling J, de la Rosette J, European Association of Urology (2013) EAU Guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms, including benign prostatic obstruction. Eur Urol 64:118\u2013140","journal-title":"Eur Urol"},{"key":"1519_CR8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1464-410X.2004.05022.x","volume":"94","author":"CR Chapple","year":"2004","unstructured":"Chapple CR (2004) Pharmacological therapy of benign prostatic hyperplasia\/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94:738\u2013744","journal-title":"BJU Int"},{"key":"1519_CR9","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0022-5347(17)36941-0","volume":"148","author":"H Lepor","year":"1992","unstructured":"Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P (1992) A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148:1467\u20131474","journal-title":"J Urol"},{"key":"1519_CR10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1464-410X.1994.tb16546.x","volume":"74","author":"CR Chapple","year":"1994","unstructured":"Chapple CR, Carter P, Christmas TJ et al (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74:50\u201356","journal-title":"Br J Urol"},{"key":"1519_CR11","first-page":"333","volume":"108","author":"SR Fine","year":"2008","unstructured":"Fine SR, Ginsberg P (2008) Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. J Am Osteopath Assoc 108:333\u2013337","journal-title":"J Am Osteopath Assoc"},{"key":"1519_CR12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.clinthera.2004.11.006","volume":"26","author":"FC Lowe","year":"2004","unstructured":"Lowe FC (2004) Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 26:1701\u20131713","journal-title":"Clin Ther"},{"key":"1519_CR13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2796.2003.01227.x","volume":"254","author":"PC Souverein","year":"2003","unstructured":"Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG (2003) Use of alpha-blockers and the risk of hip\/femur fractures. J Intern Med 254:548\u2013554","journal-title":"J Intern Med"},{"key":"1519_CR14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(03)13073-5","volume":"361","author":"A Thorpe","year":"2003","unstructured":"Thorpe A, Neal D (2003) Benign prostatic hyperplasia. Lancet 361:1359\u20131367","journal-title":"Lancet"},{"key":"1519_CR15","unstructured":"Michel MC, Gr\u00fcbbel B, M\u00f6llhoff S et al (1994) 1-Adrenoceptor affinities of drugs for the treatment of benign prostatic hyperplasia in human prostate, rat tissues and at cloned subtypes. Abstract presented at: 23rd Congress of the Soci\u00e9t\u00e9 Internationale d\u2019Urologie; September 18\u201324, Sydney, Australia. Abstract 649"},{"key":"1519_CR16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1476-5381.1994.tb17053.x","volume":"113","author":"A Hatano","year":"1994","unstructured":"Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M (1994) Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113:723\u2013728","journal-title":"Br J Pharmacol"},{"key":"1519_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1248\/yakushi.126.209","volume":"126","author":"S Tatemichi","year":"2006","unstructured":"Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N (2006) Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 126:209\u2013216","journal-title":"Yakugaku Zasshi"},{"key":"1519_CR18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez EF, European Silodosin Study Group (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59:342\u2013352","journal-title":"Eur Urol"},{"key":"1519_CR19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","volume":"98","author":"K Kawabe","year":"2006","unstructured":"Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group (2006) Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019\u20131024","journal-title":"BJU Int"},{"key":"1519_CR20","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","volume":"181","author":"LS Marks","year":"2009","unstructured":"Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G (2009) Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181:2634\u20132640","journal-title":"J Urol"},{"key":"1519_CR21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11930-007-0016-z","volume":"4","author":"J Miller","year":"2007","unstructured":"Miller J, Carson CC (2007) Alpha blockers and ejaculatory function: a state of the art review. Curr Sex Health Rep. 4:141\u2013144","journal-title":"Curr Sex Health Rep."},{"key":"1519_CR22","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1517\/14656566.2012.714368","volume":"13","author":"NI Osman","year":"2012","unstructured":"Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F (2012) Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother 13:2085\u20132096","journal-title":"Expert Opin Pharmacother"},{"key":"1519_CR23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1742-1241.2012.03012.x","volume":"67","author":"F Montorsi","year":"2013","unstructured":"Montorsi F, Mercadante D (2013) Diagnosis of BPH and treatment of LUTS among GPs: a European survey. Int J Clin Pract 67:114\u2013119","journal-title":"Int J Clin Pract"},{"key":"1519_CR24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.urology.2009.06.072","volume":"74","author":"LS Marks","year":"2009","unstructured":"Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G (2009) Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 74:1318\u20131322","journal-title":"Urology"},{"key":"1519_CR25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00003495-200666030-00002","volume":"66","author":"MM Dijk van","year":"2006","unstructured":"van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of \u03b11-adrenoceptor antagonists on male sexual function. Drugs 66:287\u2013301","journal-title":"Drugs"},{"key":"1519_CR26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/pcan.2010.46","volume":"14","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn CG, Kaplan SA, Lepor H, Volinn W (2011) Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 14:143\u2013148","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1519_CR27","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.urology.2010.03.015","volume":"76","author":"Y Homma","year":"2010","unstructured":"Homma Y, Kawabe K, Takeda M, Yoshida M (2010) Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 76:1446\u20131450","journal-title":"Urology"},{"key":"1519_CR28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.urology.2008.06.048","volume":"74","author":"WJ Hellstrom","year":"2009","unstructured":"Hellstrom WJ, Giuliano F, Rosen RC (2009) Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment. Urology 74:15\u201321","journal-title":"Urology"},{"key":"1519_CR29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0090-4295(00)01091-8","volume":"57","author":"MH Blanker","year":"2001","unstructured":"Blanker MH, Bosch JL, Groeneveld FP, Bohnen AM, Prins A, Thomas S, Hop WC (2001) Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78\u00a0years old: prevalence, concern, and relation to sexual activity. Urology 57:763\u2013768","journal-title":"Urology"},{"key":"1519_CR30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.eururo.2006.05.001","volume":"50","author":"A Hutchison","year":"2006","unstructured":"Hutchison A, Farmer R, Chapple C, Berges R, Pientka L, Teillac P, Borkowski A, Dobronski P (2006) Characteristics of patients presenting with LUTS\/BPH in six European countries. Eur Urol 50:555\u2013561","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-015-1519-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-015-1519-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-015-1519-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T01:48:10Z","timestamp":1566352090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-015-1519-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,25]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s00345-015-1519-2","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,25]]}}}